APLT

0.4101

7.01% -0.0309

Handel nachbörslich: .43 0.0199 +4.85%

Applied Therapeutics Inc (APLT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.441

Offen:

$0.421

24-Stunden-Volumen:

1.86M

Relative Volume:

0.54

Marktkapitalisierung:

$47.72M

Einnahmen:

Nettoeinkommen (Verlust:

$-119.76M

KGV:

-0.3038

EPS:

-1.35

Netto-Cashflow:

$-55.17M

1W Leistung:

-24.48%

1M Leistung:

-10.61%

6M Leistung:

-94.79%

1J Leistung:

-93.40%

1-Tages-Spanne:

$0.3952

$0.4469

1-Wochen-Bereich:

$0.3952

$0.5598

52-Wochen-Spanne:

$0.3952

$10.62

Applied Therapeutics Inc Stock (APLT) Company Profile

Firmenname

Applied Therapeutics Inc

Sektor

Healthcare (1177)

Branche

Biotechnology (678)

Telefon

212-220-9226

Adresse

545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY

Mitarbeiter

Twitter

@Applied_Tx

Nächster Verdiensttermin

2025-03-31

Neueste SEC-Einreichungen

APLT's Discussions on Twitter

Vergleichen Sie APLT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
APLT Applied Therapeutics Inc	0.4101	47.72M	0	-119.76M	-55.17M	-1.35
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-23	Herabstufung	William Blair	Outperform → Mkt Perform
2024-12-02	Herabstufung	UBS	Buy → Neutral
2024-11-29	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2024-07-31	Eingeleitet	William Blair	Outperform
2024-03-26	Eingeleitet	RBC Capital Mkts	Outperform
2024-02-22	Eingeleitet	Leerink Partners	Outperform
2022-01-04	Herabstufung	Barclays	Overweight → Equal Weight
2021-08-27	Herabstufung	Goldman	Neutral → Sell
2021-06-25	Fortgesetzt	Goldman	Neutral
2020-10-08	Eingeleitet	Truist	Buy
2020-04-22	Eingeleitet	Goldman	Buy
2020-02-27	Eingeleitet	Barclays	Overweight
2019-06-10	Eingeleitet	Citigroup	Buy
2019-06-10	Eingeleitet	Cowen	Outperform
2019-06-10	Eingeleitet	Robert W. Baird	Outperform

Alle ansehen

Applied Therapeutics Inc Aktie (APLT) Neueste Nachrichten

09:46 AM

APLT stock touches 52-week low at $0.42 amid sharp annual decline - Investing.com

09:46 AM

Apr 01, 2025

Charles Schwab Investment Management Inc. Has $600,000 Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Apr 01, 2025

Mar 31, 2025

Applied Therapeutics Delays Yearly Report Filing - TipRanks

Mar 31, 2025

Applied Therapeutics files Form 12b-25 with SEC - TipRanks

Mar 31, 2025

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewswire

Mar 31, 2025

Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results - Stock Titan

Mar 31, 2025

146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank - Defense World

Mar 31, 2025

Mar 22, 2025

Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

Mar 22, 2025

Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Mar 22, 2025

Mar 21, 2025

Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

Mar 21, 2025

APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 21, 2025

Mar 19, 2025

Applied Therapeutics appoints new Chief Regulatory Officer By Investing.com - Investing.com South Africa

Mar 19, 2025

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - citybiz

Mar 19, 2025

APLT DEADLINE ALERT: Applied Therapeutics Investors have until February 18 before Expiration of the Class Action DeadlineContact BFA Law if You Lost Money - Louisiana First News

Mar 19, 2025

Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer - Nasdaq

Mar 19, 2025

Applied Therapeutics appoints new Chief Regulatory Officer - Investing.com

Mar 19, 2025

Applied Therapeutics Strengthens Drug Approval Push With 12-Time FDA Success Veteran - Stock Titan

Mar 19, 2025

Mar 16, 2025

Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat

Mar 16, 2025

Mar 13, 2025

Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire

Mar 13, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025

Mar 12, 2025

APPLIED THERAPEUTICS Earnings Preview: Recent $APLT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 12, 2025

A look into Applied Therapeutics Inc (APLT)’s deeper side - SETE News

Mar 12, 2025

Mar 09, 2025